Affiliation:
1. Medical Institute Named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University, Lenina Boulevard 5/7, 295051 Simferopol, Russia
Abstract
Idiopathic pulmonary fibrosis remains a relevant problem of the healthcare system with an unfavorable prognosis for patients due to progressive fibrous remodeling of the pulmonary parenchyma. Starting with the damage of the epithelial lining of alveoli, pulmonary fibrosis is implemented through a cascade of complex mechanisms, the crucial of which is the TGF-β/SMAD-mediated pathway, involving various cell populations. Considering that a number of the available drugs (pirfenidone and nintedanib) have only limited effectiveness in slowing the progression of fibrosis, the search and justification of new approaches aimed at regulating the immune response, cellular aging processes, programmed cell death, and transdifferentiation of cell populations remains relevant. This literature review presents the key modern concepts concerning molecular genetics and cellular mechanisms of lung fibrosis development, based mainly on in vitro and in vivo studies in experimental models of bleomycin-induced pulmonary fibrosis, as well as the latest data on metabolic features, potential targets, and effects of vitamin D and its metabolites.
Funder
Russian Science Foundation
Reference149 articles.
1. Mei, Q., Liu, Z., Zuo, H., Yang, Z., and Qu, J. (2022). Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis. Front. Pharmacol., 12.
2. Idiopathic Pulmonary Fibrosis: Current and Future Treatment;Glass;Clin. Respir. J.,2022
3. Mortality and Survival in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis;Zheng;ERJ Open Res.,2022
4. Idiopathic Pulmonary Fibrosis in US Medicare Beneficiaries Aged 65 Years and Older: Incidence, Prevalence, and Survival, 2001–2011;Raghu;Lancet Respir. Med.,2014
5. Epidemiology of Idiopathic Pulmonary Fibrosis among U.S. Veterans, 2010–2019;Kaul;Ann. Am. Thorac. Soc.,2022